Innovent Biologics Inc. (IVBXF)
OTC: IVBXF
· Real-Time Price · USD
12.70
0.46 (3.76%)
At close: Aug 21, 2025, 3:46 PM
12.70
0.00%
After-hours: Aug 21, 2025, 04:00 PM EDT
Innovent Biologics Balance Sheet Statement
Financials in CNY. Fiscal
year is
January - December.
| Fiscal Year | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 | Q4 2022 | Q2 2022 | Q4 2021 | Q2 2021 |
| Period Ending | Dec 31, 2024 | Jun 30, 2024 | Dec 31, 2023 | Jun 30, 2023 | Dec 31, 2022 | Jun 30, 2022 | Dec 31, 2021 | Jun 30, 2021 |
Cash & Equivalents | 7.51B | 8.17B | 10.05B | 1.33B | 1.02B | 1.35B | 1.36B | 4.46B |
Short-Term Investments | 375.56M | 463.49M | 917.53M | 6.32B | 7.25B | 5.68B | 6.58B | 6.22B |
Long-Term Investments | 3.63B | 2.3B | 794.09M | -5.68B | 713.22M | 465M | 511.9M | -6.17B |
Other Long-Term Assets | 774.02M | 537.42M | 1.72B | 6.55B | 110.04M | 78.18M | -4.33B | 6.38B |
Receivables | 1.57B | 1.37B | 1.01B | 1.02B | 575.27M | 1.19B | 968.4M | 1B |
Inventory | 822.17M | 690.41M | 968.09M | 1.3B | 1.43B | 1.48B | 1.35B | 1.1B |
Other Current Assets | n/a | 360.55M | 484.38M | 2.43B | 1.81B | 2.47B | 975.04M | 1.48B |
Total Current Assets | 10.27B | 11.05B | 13.43B | 11.39B | 11.51B | 11.19B | 11.55B | 13.43B |
Property-Plant & Equipment | 5.65B | 5.42B | 4.66B | 4.45B | 4.06B | 3.61B | 3.38B | 2.72B |
Goodwill & Intangibles | 1.28B | 987.35M | 27.79M | 1.19B | 1.2B | 815.5M | 772.19M | 96.91M |
Total Long-Term Assets | 11.33B | 9.25B | 7.2B | 6.51B | 6.08B | 4.96B | 4.69B | 3.02B |
Total Assets | 21.6B | 20.3B | 20.63B | 17.9B | 17.59B | 16.16B | 16.24B | 16.46B |
Account Payables | 357.68M | 220.62M | 372.55M | 216.41M | 325.62M | 236.35M | 195.05M | 277.33M |
Deferred Revenue | n/a | n/a | n/a | n/a | n/a | n/a | -1.03B | n/a |
Short-Term Debt | 405.1M | 934.65M | 1.2B | 450.1M | 888M | 858M | 365M | 370M |
Other Current Liabilities | 2.32B | 829.58M | 2.02B | 1.47B | 1.64B | 1.9B | 1.71B | 961.99M |
Total Current Liabilities | 4.37B | 4.13B | 4.48B | 2.87B | 3.5B | 3.48B | 3.05B | 2.24B |
Long-Term Debt | 2.41B | 2.27B | 2.33B | 2.89B | 2.22B | 1.81B | 2.02B | 1.47B |
Other Long-Term Liabilities | 1.7B | 1.4B | 1.22B | 1.27B | 1.05B | 1.19B | 342K | n/a |
Total Long-Term Liabilities | 4.12B | 3.74B | 3.62B | 4.24B | 3.36B | 3.09B | 2.86B | 2.31B |
Total Liabilities | 8.48B | 7.87B | 8.1B | 7.11B | 6.86B | 6.57B | 5.91B | 4.55B |
Total Debt | 2.83B | 3.35B | 3.62B | 3.45B | 3.23B | 2.77B | 2.5B | 1.86B |
Common Stock | 113K | 112K | 112K | 106K | 105K | 101K | 101K | 100K |
Retained Earnings | n/a | -16.16B | -15.77B | -14.88B | -16.68B | -15.82B | -15.41B | -11.16B |
Comprehensive Income | n/a | 1.04B | n/a | 761.76M | 763.86M | 558.15M | 397.02M | 595.2M |
Shareholders Equity | 13.12B | 12.43B | 12.53B | 10.78B | 10.73B | 9.59B | 10.33B | 11.91B |
Total Investments | 3.9B | 2.76B | 794.09M | 636.65M | 630.2M | 397.05M | 417.25M | 45.43M |